Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kim Cranston Bio: Promoted from Director to CEO
Mr. Kim Cranston is Director of Bizzingo, Inc. Mr. Cranston is C.E.O. and Chair of the Board of Transparent Democracy, Chair of the Board of the Global Security Institute, and a member of the Boards of The Climate Response Fund and of the Los Altos Community Foundation. Mr. Cranston graduated from the University of California Santa Cruz with a B.A. in Environmental Studies and from Hastings College of the Law
Cranston previously held positions as director of Corporationrationrate Social Responsibility and the Transparent Commerce Initiative for One Cosmos Network, a new media company; as President of the Social Venture Network, a network of socially conscious business and social entrepreneurs and investors; as a consultant to the State of the World Forum; as Chief of Staff to California Lieutenant Governor Leo T. McCarthy; as Vice President of Business Affairs for Platypus Productions, Inc., a cable television production company; and as a lawyer with Gibson, Dunn & Crutcher.
http://www.bizzingo.com/corp/index.html%3Fp=365.html
http://www.huffingtonpost.com/kim-cranston
http://www.gsinstitute.org/gsi/directors.html
8K out ~ Effective January 16, 2013, Bizzingo, Inc. appointed Kim Cranston as its Chairman of the Company’s Board of Directors. Concurrent with the stated appointment, Mr. Douglas Toth resigned as the Company’s Chairman , however remains as the Company’s Vice Chairman.
Effective January 16, 2013, Bizzingo, Inc. appointed Dipak Joshi as its Chief Financial Officer. Concurrent with the stated appointment, Mr. Douglas Toth resigned as the Company’s Chief Financial Officer, however remains as the Company’s Vice Chairman.
Mr. Dipak Joshi
Dipak is an experienced professional with more than 20 years of experience in public technology companies. His knowledge of finance spans Security Systems, eCommerce, Digital Advertising, and Enterprise Web Conferencing. He began in accounting in controller functions at Siemens. He moved to eCommerce at eBay, focused on M&A, before joining Google’s finance department. Recently, he served as SVP Finance for FuzeBox, a web conferencing start-up.
Dipak holds a Bachelor’s degree in both Management & Chemical Sciences from The University of Manchester Institute of Science & Technology. He also holds an MBA from Duke University.
Jerry Monday's response to this fiasco, perpetuated by some morons on this board...what a joke!
On Jan 15, 2013, at 1:22 PM, TKD <XXXXXXXXXXXenterprises@yahoo.com> wrote:
Jerry,
I'm hearing the GNE asset purchase deal is dead. Can you confirm a new direction for you and the co?
Kind regards,
XXXXXXX
His response:
Yes
Sent from my iPhone
I concur. Dunno why they even put it up for proxy vote??? But they must have their reason(s). They almost take away potential liquidity by making it any smaller....IMO
Gotta lil starter position the other day....could start getting interesting in here....
I could be wrong, but I think the highest RS was to be 1:6
If true, the warrants would have to be exercised in order to receive the divvy shares...IMO
Where did you get that info? tia
So I assume one of the items voted on was the RS? Wonder how that will play out.
Agreed. Thx
Great. Thx!
So, this cert call for name change seems odd. IMO, the PR is poorly worded again; shouldn't it read Certs need to be sent in to get the Divvy shares in the BVI co?
Yeah, email him and let us know if the atty is still eyeballin the PR....lol
Still no reply....not sure he would have replied to it, though. He typically responds in about 20 mins or less....try him, jerrymonday@aol.com
NEWS ~
Proteonomix To Require Physical Exchange Of Certificates
Date : 01/10/2013 @ 11:49AM
Source : PR Newswire (US)
Stock : Proteonomix, Inc. (PC) (PROT)
Quote : 0.6 -0.06 (-9.09%) @ 11:21AM
PARAMUS, N.J., Jan. 10, 2013 /PRNewswire/ -- Proteonomix, Inc. (the "Company") (OTC Pink: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that upon its name change to StromaCel, Inc., presently scheduled for January 18, 2013, all shareholders will be required to submit their stock certificates to our transfer agent, VStock Transfer, in order to obtain their new share certificates in the Company.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. StromaCel, our subsidiary, develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. National Stem Cell, Inc. is prosecuting patent applications licensed to it.
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
SOURCE Law Offices of Roger L. Fidler
Thanks Lee! Hope you are doing well, Sir!
What was the pps back when folks bought during the encapsol days? TIA
Very nice read! Thanks for taking the time and effort to write that up for us! Sounds like it will be an extremely fun ride going forward. My best to you and us all. Go $PROT
Hey there Fin, I dunno about S. Texas, Eagle Ford area, but it's been raining for three days straight in Houston. No real correlation I suppose, just made me think of water!!!! Sure would like to hear what is going on with the sales, and any jv's that they are potentially involved in and some NAMES to go with those partnerships assuming they exist. Been pretty patient, but ready to receive an update, too. Have a great day, Sir!
Great. Sorry for the confusion. I standby what he told me yesterday, perhaps there was some miscommunication between us. Thanks for the clarity.
You guys need to read slowly and see that what you are inferring, is in fact wishful thinking. It does not (clearly) state anything obvious, that is for sure. I will leave it alone for now....hope I'm wrong, and that the best result comes to us all. (However, I think the new entity is the gold mind! ) So we should all be good either way. See ya'll tmrw...
Wrong, respectfully, Based on my 30 minute discussion with the co. Call tmrw and ask specific questions, as I did. Just ASK, Which co will be called StromaCel? The new co or the existing PROT...I was clearly told that the new co will be called StromaCel....You guys are thinking this is a dividend of sorts, IMO it is NOT. That would be super Sweet, but I do not think that is the case, unfortunately. If I'm wrong, I'll eat crow, lots of it! I hope I'm wrong, but doubt I will be. All IMO
Doubt it, aologize when Im right, lol
Roger Fidler, Ill be out the remainder of the night. Guess we will find out more tmrw....cheers
I do believe the opposite. And yes it was written poorly, but StromaCel is the new entity (I think) and there will be no surviving entity....straight from the horses mouth, so to speak. If I'm wrong, I apologize in advance.
I was definitely told the new co is the one that will be called StromaCel with all the PROT liver, heart, cancer trials going into that entity, by Roger Fidler....I'm fairly certain my post is accurate, but I could be wrong.
So, after researching this a bit more (cause I'm slow...lol) PROT is going away as currently traded on the otcmarket and all the intellectual properties/patents are going into the new entity which will be called StromaCel, and will trade as a BVI (British Virgin Islands) Corp overseas in the UK on the GXG exchange, I'm told. All shares purchased by Friday(3 day rule doesn't apply in this case Im told, but don't quote me, call your Broker) in what is currently PROT will be transferred over to the new company when that exchange is up and running, which I'm told will hopefully be sometime next week. The share structure for the new company is said to be about the same as the current SS of PROT.
Is this your take on events forthcoming??
LOL, right! I wish I had sold this thing on the bod hype! Damnit!
65's print! Go $PROT
NE1 heard from JM lately? I emailed yesterday and didn't get a reply back like usual (within 20 mins).
Oh, I certainly agree. However, it should be interesting to see what transpires in the next three days. Then all the trials news , including heart and cancer, homerun IMO!
Nice post! I suspect we will start seeing short covering very soon. http://otcshortreport.com/PROT
I would say, yes, the shorts will have to cover by close on Friday. I'm no expert, but it would make sense to me. I think this new spin off may be huge! Let's hope so! Go $PROT
1for 1 shares in new company - Stromacel effective date 1/11/12
NEWS ~
Proteonomix Announces Restructuring
Date : 01/08/2013 @ 9:42AM
Source : PR Newswire (US)
Stock : Proteonomix, Inc. (PC) (PROT)
Quote : 0.6 0.0 (0.00%) @ 5:32AM
Proteonomix Announces Restructuring
Proteonomix, Inc. (PC) (USOTC:PROT)
Intraday Stock Chart
Today : Tuesday 8 January 2013
Click Here for more Proteonomix, Inc. (PC) Charts.
PARAMUS, N.J., Jan. 8, 2013 /PRNewswire/ -- Proteonomix, Inc. (the "Company") (SYMBOL: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has caused the formation of a BVI corporation that will receive sublicenses and assignments of technology previously licensed to the Company so as to facilitate future financing and operations.
Michael Cohen, President and CEO of the Company, stated, "We formed a BVI corporation, Proteonomix, Ltd., that will issue to all shareholders of record at the close of business on January 11, 2013, the same number of shares that they own at the close on that date, without further payment of any sort whatsoever." "We have decided to do this to assure shareholders that the new sublicenses and assignments of licenses to the BVI corporation will not impact such shareholders' participation in the successes, or failures, of the Company's present clinical trial or our planned future activities." "We plan to leave the StromaCel technology in the Company and change the name of the Company to StromaCel, Inc. The diabetes technology present in the licensed technology left behind is what started me on the quest that became our Company. We intend to continue this work, which will hopefully culminate with a solution to Type I diabetes that has my wife among its victims. This Company began many years ago with the intent to cure her and my commitment to continue that work is still resolute."
Mr. Roger Fidler, General Counsel and Treasurer of the Company, stated: "We undertake this restructuring and will establish a trading market outside of the United States on the GXG, to seek financing outside of the United States. At this point we have cash on hand sufficient to seek additional offshore financing in order to advance the current and future IP that the company has licensed."
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at www.proteonomix.com and www.proteoderm.com.
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
An agenda I think....lol We should start heating up this month! Looking forward to some solid updates soon. All IMO
The optimal word being merger! Yes there is some asset transaction supposedly going on between GNE and THCB, but no merger has ever been put out in any PR that Ive seen.
I hear ya. Ive talked to JM a couple of times via email and he stated he didn't know where the GNE merger talk was coming from....I know where it came from....some message board poster! Anyway, he did say that the atty has the PR...so it should be tmrw after hours if it's weak (lol, just like politicians) or early next week if they think it has some meat to it. We'll see....hate to start off the year with my tax loss all ready to go!!!
Why would you need an atty?? LOL It all doesn't pass the smell test IMO I supposed an atty may be needed, but damn, it doesn't take this long. All I expect from the PR is name change, BOD and SH approval for RS, and possibly asset swap, but I doubt the asset swap comes in the first PR.